Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models

Cancer Science

Volumn 102, Issue 3, 2011, Pages 614-621

  Nakahara, Takahito ^a   Kita, Aya ^a   Yamanaka, Kentaro ^a   Mori, Masamichi ^a   Amino, Nobuaki ^a   Takeuchi, Masahiro ^a   Tominaga, Fumiko ^a   Kinoyama, Isao ^a   Matsuhisa, Akira ^a   Kudou, Masafumi ^a   Sasamata, Masao ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 METHOXYETHOXY) 2 METHYL 3 (2 PYRAZINYLMETHYL)NAPHTHO[2,3 D]IMIDAZOLE 4,9 DIONE; ANTINEOPLASTIC AGENT; PROTEIN P53; SURVIVIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; LEUKEMIA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MITOSIS INDEX; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; NULL CELL; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SARCOMA; TUMOR REGRESSION; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; GENES, P53; HUMANS; IMIDAZOLES; MALE; MICE; MICE, INBRED BALB C; MICROTUBULE-ASSOCIATED PROTEINS; NAPHTHOQUINONES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79951717493     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01834.x     Document Type: Article

References (44)

1. Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 1997; 3: 917-21.
2. Blanc-Brude OP, Mesri M, Wall NR, Plescia J, Dohi T, Altieri DC. Therapeutic targeting of the survivin pathway in cancer: initiation of mitochondrial apoptosis and suppression of tumor-associated angiogenesis. Clin Cancer Res 2003; 9: 2683-92.
3. Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions. Carcinogenesis 2007; 28: 1133-9.
4. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 1998; 58: 5071-4.
5. Adida C, Haioun C, Gaulard P et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000; 96: 1921-5.
6. Takai N, Miyazaki T, Nishida M, Nasu K, Miyakawa I. Survivin expression correlates with clinical stage, histological grade, invasive behavior and survival rate in endometrial carcinoma. Cancer Lett 2002; 184: 105-16.
7. Tanaka K, Iwamoto S, Gon G, Nohara T, Iwamoto M, Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000; 6: 127-34.
8. Span PN, Sweep FC, Wiegerinck ET et al. Survivin is an independent prognostic marker for risk stratification of breast cancer patients. Clin Chem 2004; 50: 1986-93.
9. Ferrandina G, Legge F, Martinelli E et al. Survivin expression in ovarian cancer and its correlation with clinico-pathological, surgical and apoptosis-related parameters. Br J Cancer 2005; 92: 271-7.
10. Lu CD, Altieri DC, Tanigawa N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 1998; 58: 1808-12.
11. Monzo M, Rosell R, Felip E et al. A novel anti-apoptosis gene: re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers. J Clin Oncol 1999; 17: 2100-4.
12. Tamm I, Wang Y, Sausville E et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-20.
13. Nakahara T, Takeuchi M, Kinoyama I et al. YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. Cancer Res 2007; 67: 8014-21.
14. Monks A, Scudiero D, Skehan P et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991; 83: 757-66.
15. Skehan P, Storeng R, Scudiero D et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990; 82: 1107-12.
16. Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH. Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods 1997; 208: 151-8.
17. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P. The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat 2002; 19: 607-14.
18. O'Connor PM, Jackman J, Bae I et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57: 4285-300.
19. Paduano F, Villa R, Pennati M et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells. Mol Cancer Ther 2006; 5: 179-86.
20. Olie RA, Simoes-Wust AP, Baumann B et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res 2000; 60: 2805-9.
21. Grossman D, Kim PJ, Schechner JS, Altieri DC. Inhibition of melanoma tumor growth in vivo by survivin targeting. Proc Natl Acad Sci U S A 2001; 98: 635-40.
22. Ansell SM, Arendt BK, Grote DM et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004; 18: 616-23.
23. Fuessel S, Herrmann J, Ning S et al. Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA. Cancer Lett 2006; 232: 243-54.
24. Ma X, Wang S, Zhou J et al. Induction of apoptosis in human ovarian epithelial cancer cells by antisurvivin oligonucleotides. Oncol Rep 2005; 14: 275-9.
25. Mesri M, Wall NR, Li J, Kim RW, Altieri DC. Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 2001; 108: 981-90.
26. Liu WS, Yan HJ, Qin RY, et al. siRNA directed against survivin enhances pancreatic cancer cell gemcitabine chemosensitivity. Dig Dis Sci 2009; 54: 89-96.
27. Minematsu T, Iwai M, Sugimoto K et al. Carrier-mediated uptake of 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho[2, 3-d]imidazolium bromide (YM155 monobromide), a novel small-molecule survivin suppressant, into human solid tumor and lymphoma cells. Drug Metab Dispos 2009; 37: 619-28.
28. Minematsu T, Iwai M, Umehara KI, Usui T, Kamimura H. Characterization of human organic cation transporter 1 (OCT1/SLC22a1)-, and OCT2 (SLC22a2)-mediated transport of 1-(2-methoxyethyl)-2-methyl-4, 9-dioxo-3-(pyrazin-2-ylmethyl)-4, 9-dihydro-1H-naphtho[2, 3-d]imidazolium bromide (YM155 monobromide), a novel small molecule survivin suppressant. Drug Metab Dispos 2010; 38: 1-4.
29. Steele RJ, Thompson AM, Hall PA, Lane DP. The p53 tumour suppressor gene. Br J Surg 1998; 85: 1460-7.
30. Huncharek M, Kupelnick B, Geschwind JF, Caubet JF. Prognostic significance of p53 mutations in non-small cell lung cancer: a meta-analysis of 829 cases from eight published studies. Cancer Lett 2000; 153: 219-26.
31. Mitsudomi T, Hamajima N, Ogawa M, Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 2000; 6: 4055-63.
32. Pharoah PD, Day NE, Caldas C. Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer 1999; 80: 1968-73.
33. Zhou M, Gu L, Li F, Zhu Y, Woods WG, Findley HW. DNA damage induces a novel p53-survivin signaling pathway regulating cell cycle and apoptosis in acute lymphoblastic leukemia cells. J Pharmacol Exp Ther 2002; 303: 124-31.
34. Mirza A, McGuirk M, Hockenberry TN et al. Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway. Oncogene 2002; 21: 2613-22.
35. Hoffman WH, Biade S, Zilfou JT, Chen J, Murphy M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J Biol Chem 2002; 277: 3247-57.
36. Weinstein JN, Myers TG, O'Connor PM et al. An information-intensive approach to the molecular pharmacology of cancer. Science 1997; 275: 343-9.
37. Yonesaka K, Tamura K, Kurata T et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006; 118: 812-20.
38. Li H, Niederkorn JY, Neelam S, Alizadeh H. Downregulation of survivin expression enhances sensitivity of cultured uveal melanoma cells to cisplatin treatment. Exp Eye Res 2006; 83: 176-82.
39. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, Borden EC. Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 2004; 11: 915-23.
40. Iwasa T, Okamoto I, Suzuki M et al. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines. Clin Cancer Res 2008; 14: 6496-504.
41. Tolcher AW, Mita A, Lewis LD et al. Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J Clin Oncol 2008; 26: 5198-203.
42. Satoh T, Okamoto I, Miyazaki M et al. Phase I study of YM155, a novel survivin suppressant, in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 3872-80.
43. Giaccone G, Zatloukal P, Roubec J et al. Multicenter phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J Clin Oncol 2009; 27: 4481-6.
44. Lewis KD, Samlowski W, Ward J, et al. A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma. Invest New Drugs 2009. [Epub ahead of print].